AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Global Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Clinical Trials Review, H2, 2018 - ResearchAndMarkets.com

February 26, 2019

DUBLIN--(BUSINESS WIRE)--Feb 26, 2019--The “Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, H2, 2018” clinical trials has been added to ResearchAndMarkets.com’s offering.

“Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Global Clinical Trials Review, H2, 2018” provides an overview of Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). These reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Key Topics Covered:

  1. List of Tables
  2. List of Figures
  3. Report Guidance
  4. Clinical Trials Report Coverage
  5. Clinical Trials by Region
  6. Clinical Trials and Average Enrollment by Country
  7. Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  8. Top Five Countries Contributing to Clinical Trials in Europe
  9. Top Countries Contributing to Clinical Trials in North America
  10. Top Countries Contributing to Clinical Trials in Middle East and Africa
  11. Top Countries Contributing to Clinical Trials in Central and South America
  12. Clinical Trials by G7 Countries: Proportion of Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy to Oncology Clinical Trials
  13. Clinical Trials by Phase in G7 Countries
  14. Clinical Trials in G7 Countries by Trial Status
  15. Clinical Trials by E7 Countries: Proportion of Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy to Oncology Clinical Trials
  16. Clinical Trials by Phase in E7 Countries
  17. Clinical Trials in E7 Countries by Trial Status
  18. Clinical Trials by Phase
  19. In Progress Trials by Phase
  20. Clinical Trials by Trial Status
  21. Clinical Trials by End Point Status
  22. Subjects Recruited Over a Period of Time
  23. Clinical Trials by Sponsor Type
  24. Prominent Sponsors
  25. Top Companies Participating in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Therapeutics Clinical Trials
  26. Prominent Drugs
  27. Clinical Trial Profile Snapshots
  28. Appendix

Companies Mentioned

  • Celgene Corp
  • Takeda Pharmaceutical Co Ltd
  • Merck & Co Inc
  • Novartis AG
  • Seattle Genetics Inc
  • Sanofi
  • Nordic Lymphoma Group
  • Mundipharma International Ltd
  • Kirin Holdings Co Ltd
  • Chipscreen Biosciences Ltd

For more information about this clinical trials report visit https://www.researchandmarkets.com/research/97qfp4/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190226005581/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Clinical Trials

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/26/2019 06:45 AM/DISC: 02/26/2019 06:46 AM

http://www.businesswire.com/news/home/20190226005581/en